The JAK-STAT (Janus kinase–Signal Transducer and Activator of Transcription) signaling pathway represents one of the most critical cytokine-responsive mechanisms in the central nervous system, and its dysregulation is increasingly recognized as a central feature of 4R-tauopathies. This page provides a cross-disease comparison of JAK-STAT pathway activation and the broader cytokine milieu across [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) (AGD), [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy) (GGT), and FTDP-17T ([MAPT](/genes/mapt) mutations).
The JAK-STAT pathway transduces extracellular cytokine signals—including [IL-6](/mechanisms/il-6-signaling-neurodegeneration), [IL-1β](/mechanisms/il-1-signaling-neurodegeneration), [TNF-α](/mechanisms/tnf-signaling-neurodegeneration), and interferons—into transcriptional responses that regulate neuroinflammation, glial reactivity, and importantly, tau phosphorylation dynamics. In 4R-tauopathies, chronic JAK-STAT activation creates a self-reinforcing inflammatory loop: cytokines drive tau hyperphosphorylation through stress kinase pathways, while tau aggregates further activate microglia and astrocytes, releasing more inflammatory mediators[@qin2016]. This cross-talk between cytokine signaling and tau pathology makes JAK-STAT a compelling therapeutic target.
The JAK-STAT (Janus kinase–Signal Transducer and Activator of Transcription) signaling pathway represents one of the most critical cytokine-responsive mechanisms in the central nervous system, and its dysregulation is increasingly recognized as a central feature of 4R-tauopathies. This page provides a cross-disease comparison of JAK-STAT pathway activation and the broader cytokine milieu across [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (PSP), [Corticobasal Degeneration](/diseases/corticobasal-degeneration) (CBD), [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease) (AGD), [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy) (GGT), and FTDP-17T ([MAPT](/genes/mapt) mutations).
The JAK-STAT pathway transduces extracellular cytokine signals—including [IL-6](/mechanisms/il-6-signaling-neurodegeneration), [IL-1β](/mechanisms/il-1-signaling-neurodegeneration), [TNF-α](/mechanisms/tnf-signaling-neurodegeneration), and interferons—into transcriptional responses that regulate neuroinflammation, glial reactivity, and importantly, tau phosphorylation dynamics. In 4R-tauopathies, chronic JAK-STAT activation creates a self-reinforcing inflammatory loop: cytokines drive tau hyperphosphorylation through stress kinase pathways, while tau aggregates further activate microglia and astrocytes, releasing more inflammatory mediators[@qin2016]. This cross-talk between cytokine signaling and tau pathology makes JAK-STAT a compelling therapeutic target.
The JAK family comprises four non-receptor tyrosine kinases—JAK1, JAK2, JAK3, and TYK2—that associate with cytokine receptors and mediate downstream signal transduction. In the brain, JAK1 and JAK2 are the most relevant to neurodegeneration, as they are widely expressed in [neurons](/cell-types/neurons), [microglia](/cell-types/microglia), and [astrocytes](/entities/astrocytes)[@nguyen2019].
| Kinase | Primary Cell Types | Key Cytokine Inputs | Role in 4R-Tauopathies |
|--------|--------------------|--------------------|-----------------------|
| JAK1 | Ubiquitous (neurons, glia) | IL-6, IL-10, IFNs | Pro-inflammatory; mediates IL-6-driven tau phosphorylation |
| JAK2 | Ubiquitous (neurons, glia) | IL-3, IL-12, EPO, GM-CSF | Mitochondrial stress response; involved in microglial activation |
| TYK2 | Lower expression in CNS | Type I IFNs, IL-10, IL-12 | Contributes to IFN-driven neuroinflammation |
| JAK3 | Primarily lymphoid | γc cytokines | Limited role in brain parenchyma |
STAT proteins are the primary effectors of JAK-STAT signaling. Upon JAK-mediated tyrosine phosphorylation, STATs dimerize and translocate to the nucleus to regulate gene expression.
PSP demonstrates the most robust JAK-STAT activation among 4R-tauopathies, consistent with its aggressive neuroinflammatory profile.
JAK2/STAT3 axis: Elevated phospho-JAK2 and phospho-STAT3 are consistently observed in PSP brainstem nuclei, basal ganglia, and cerebellar dentate nucleus[@fernandez2025]. STAT3 activation correlates with disease severity and tau pathology burden. The IL-6/JAK2/STAT3 axis is particularly prominent, with IL-6 levels elevated in both postmortem brain tissue and CSF[@tanaka2024].
Tau phosphorylation crosstalk: IL-1β-mediated JAK2 activation drives tau phosphorylation through intersecting pathways, including GSK-3β and CDK5 activation[@chen2024a]. This creates a feedforward loop where neuroinflammation accelerates tau pathology, which in turn drives further microglial activation.
Microglial STAT3: Single-nucleus RNA sequencing of PSP brains identifies a microglial cluster with heightened STAT3 pathway activity, distinct from disease-associated microglia (DAM) signatures[@zhang2024a]. These "STAT3-high" microglia show elevated expression of pro-inflammatory cytokines and are enriched in regions with high tau burden.
CBD shows distinct JAK-STAT activation patterns with asymmetric distribution reflecting the characteristic hemispheric asymmetry of the disease.
JAK1/STAT1 signaling: Unlike PSP's JAK2/STAT3 predominance, CBD shows more prominent JAK1 and STAT1 activation, consistent with its IFN-γ-driven inflammatory profile[@lopez2022]. STAT1 activation is observed in affected cortical regions and correlates with the degree of cortical atrophy.
Asymmetric activation: JAK-STAT pathway activation is notably stronger in the more affected hemisphere, paralleling the asymmetric tau pathology characteristic of CBD.
Mixed microglial phenotype: CBD microglia show a mixed M1/M2 phenotype with JAK-STAT signaling driving both pro-inflammatory responses and attempted neuroprotective functions. TREM2 expression modulates this balance[@muller2024].
AGD demonstrates a more restricted JAK-STAT activation pattern, consistent with its generally milder inflammatory profile compared to PSP and CBD.
Modest activation: JAK-STAT pathway activation in AGD is less pronounced than in PSP or CBD, with primary involvement of limbic structures (hippocampus, entorhinal cortex, amygdala)[@baker2023]. STAT3 activation is detectable but at lower levels than in PSP.
Cytokine milieu: The IL-1β and TNF-α elevations are mild compared to PSP[@tanaka2024], which may contribute to AGD's slower clinical progression. SOCS3 upregulation is also less prominent, suggesting a weaker compensatory feedback response.
Astrocytic involvement: Astrocytic JAK-STAT activation in AGD is primarily associated with the limbic system and correlates with the presence of argyrophilic grains in astrocytic processes[@sato2024].
GGT presents unique JAK-STAT activation patterns given its primary glial pathology.
Oligodendroglial JAK-STAT: GGT's characteristic globular oligodendroglial inclusions (GOIs) and globular astroglial inclusions (GAIs) are associated with JAK-STAT pathway activation in both oligodendrocytes and astrocytes. JAK2 and STAT3 are detected in the cytoplasmic inclusions themselves[@sato2024].
White matter inflammation: JAK-STAT activation in GGT is prominent in affected white matter tracts, differentiating it from the gray matter-predominant patterns in PSP and CBD.
Myelin dysfunction crosstalk: JAK-STAT signaling intersects with myelin dysfunction pathways. JAK2 activation in oligodendrocytes contributes to the GOI formation process, potentially linking cytokine signaling to the unique globular tau inclusions characteristic of GGT.
FTDP-17T demonstrates mutation-specific JAK-STAT activation patterns that provide mechanistic insight into how different MAPT mutations influence inflammatory responses.
Mutation-specific profiles: Different MAPT mutations produce varying degrees of JAK-STAT activation. P301L and P301S mutations are associated with more robust microglial JAK-STAT activation than V337M, correlating with their respective disease aggressiveness.
Neuronal STAT3: Neuronal STAT3 activation is observed in FTDP-17T, with both cell-autonomous effects (direct consequences of mutant tau) and non-cell-autonomous effects (microglial and astrocyte-derived cytokines) contributing to the signaling landscape.
Limited astrocytic pathology: Unlike PSP and CBD, FTDP-17T typically shows minimal primary astrocytic JAK-STAT involvement, with inflammation driven primarily by microglial activation and neuronal distress signals[@sato2024].
The cytokine profiles across 4R-tauopathies reveal disease-specific signatures that drive JAK-STAT activation patterns. CSF and postmortem brain studies have identified distinct cytokine milieus[@tanaka2024][@correia2024]:
| Cytokine | PSP | CBD | AGD | GGT | FTDP-17T | Pathway |
|----------|-----|-----|-----|-----|----------|---------|
| IL-6 | +++ | ++ | + | ++ | ++ | JAK1/JAK2 |
| IL-1β | +++ | ++ | + | ++ | ++ | JAK2 |
| TNF-α | +++ | ++ | + | ++ | + | JAK1/JAK2 |
| IFN-γ | ++ | +++ | - | + | + | JAK1/STAT1 |
| IL-10 | + | + | ++ | + | + | JAK1 (anti-inflammatory) |
| TGF-β | + | + | ++ | + | + | JAK1 (anti-inflammatory) |
| IL-12 | ++ | ++ | + | + | + | JAK2/TYK2 |
| CXCL8 (IL-8) | ++ | ++ | + | ++ | + | JAK1/STAT1 |
| MCP-1 (CCL2) | +++ | ++ | + | ++ | ++ | JAK1/STAT1 |
Legend: +++ = highly elevated; ++ = moderately elevated; + = mildly elevated; - = not significantly elevated
Key patterns:
Microglial JAK-STAT signaling plays a critical role in determining the functional phenotype of microglia in 4R-tauopathies. The JAK-STAT pathway integrates signals from cytokines, damage-associated molecular patterns (DAMPs), and cell surface receptors (including TREM2) to drive microglial polarization toward distinct functional states[@muller2024][@kim2024].
Pro-inflammatory (M1-like) polarization: IL-6 and IL-1β signaling through JAK1/JAK2 drives STAT3 phosphorylation, which promotes transcription of pro-inflammatory genes including TNF-α, IL-1β, and iNOS. This creates a feedforward loop where M1-like microglia release cytokines that further activate JAK-STAT[@qin2016].
Disease-Associated Microglia (DAM): In 4R-tauopathies, a specific microglial phenotype—the DAM—has been characterized by single-nucleus RNA sequencing. DAM cells show elevated TREM2 expression and are associated with a protective phagocytic response. JAK-STAT signaling modulates the transition between DAM and M1-like states: STAT3 activation initially promotes DAM-like functions, but chronic STAT3 activation pushes microglia toward an M1-like pro-inflammatory state[@zhang2024a][@kim2024].
TREM2 modulation of JAK-STAT: TREM2 signaling intersects with JAK-STAT through the TYROBP (DAP12) adaptor protein. TREM2 engagement can suppress excessive JAK-STAT activation, promoting a more neuroprotective microglial phenotype. In PSP, TREM2 R47H variant carriers show hyper-reactive JAK-STAT responses to tau aggregates, with elevated STAT3 phosphorylation and more aggressive disease progression[@muller2024].
| Disease | Dominant Microglial State | JAK-STAT Pattern | TREM2 Status |
|---------|-------------------------|-----------------|--------------|
| PSP | M1-like, DAM-enriched | JAK2/STAT3 high | R47H variant increases risk |
| CBD | Mixed M1/M2 | JAK1/STAT1 high | Reduced TREM2 signaling |
| AGD | Mildly reactive | Low JAK-STAT | Normal |
| GGT | Oligodendrocyte-focused | JAK2 in glia | Variable |
| FTDP-17T | Mutation-dependent | Varies by mutation | Normal |
One of the most therapeutically significant connections in 4R-tauopathies is the bidirectional cross-talk between JAK-STAT signaling and tau pathology. This cross-talk creates self-reinforcing pathogenic loops.
IL-1β-mediated tau phosphorylation: IL-1β binding to its receptor activates JAK2, which in turn activates downstream stress kinases including p38 MAPK, JNK, and GSK-3β. These kinases phosphorylate tau at multiple epitopes, including Ser396, Thr231, and Ser202, promoting its aggregation into insoluble filaments[@chen2024a].
IL-6-driven STAT3 and tau: IL-6 activates STAT3 both directly (through JAK1/JAK2) and indirectly through astrocyte-derived signals. Neuronal STAT3 activation promotes expression of CDK5 and other kinases that phosphorylate tau. Additionally, STAT3 upregulates expression of the phosphatases PP2A, which further disrupts tau homeostasis[@yang2023][@zhang2025a].
TNF-α amplification: TNF-α signaling through JAK1 amplifies both microglial activation and neuronal stress responses. TNF-α-mediated STAT3 activation in neurons promotes mitochondrial dysfunction and oxidative stress, which further accelerates tau pathology.
Astrocytes are both targets and sources of cytokine signaling in 4R-tauopathies. The JAK-STAT pathway plays a central role in astrocyte reactivity, contributing to both the A1 neurotoxic phenotype and the disease-specific astrocytic lesions observed in PSP, CBD, and GGT[@sato2024][@zhang2025a].
The A1 neurotoxic astrocyte phenotype is induced by microglial-derived cytokines—IL-1α, TNF-α, and C1q—which signal through astrocyte JAK-STAT pathways:
JAK inhibitors represent a promising therapeutic approach for 4R-tauopathies by interrupting the self-reinforcing cycle of cytokine signaling and tau pathology. Multiple agents have been evaluated or are under investigation.
| Drug | Primary Target | Evidence in 4R-Tauopathies | Clinical Status |
|------|---------------|---------------------------|----------------|
| Baricitinib | JAK1/JAK2 | Phase 2 RCT in PSP showing reduced CSF cytokines and slower clinical decline[@williams2025] | Phase 2 completed |
| Tofacitinib | JAK1/JAK3 | Reduced microglial activation and tau pathology in P301S tauopathy mouse model[@johnson2024] | Preclinical |
| Ruxolitinib | JAK1/JAK2 | Dose-dependent reduction in microglial inflammation and enhanced tau clearance in primary cultures[@hernandez2025] | Preclinical |
| Filgotinib | JAK1 | Under evaluation; BBB penetration being assessed | Early preclinical |
BBB penetration: All JAK inhibitors were developed for peripheral inflammatory diseases. CNS penetration varies significantly between agents. Baricitinib has demonstrated better CNS penetration than tofacitinib, making it the current leading candidate for 4R-tauopathies.
Timing and disease stage: Preclinical data suggest JAK inhibitors are most effective early in disease, when neuroinflammation drives pathology progression. Late-stage intervention may be less effective due to established structural damage.
Cell-type specificity: Achieving sufficient CNS exposure while avoiding systemic immunosuppression remains challenging. Newer JAK inhibitors with selective CNS exposure profiles are in development.
Combination approaches: JAK inhibitors may synergize with anti-tau therapies, as interrupting the cytokine-tau cross-talk loop addresses two pathological axes simultaneously.
The following diagram shows the key molecular relationships involving JAK-STAT and Cytokine Signaling in 4R-Tauopathies discovered through SciDEX knowledge graph analysis: